Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Big Pharma, big problems

- Featured Image

This Enlightening, Alarming and depressing book deserves a wide readership among doctors but also among politicians, health administrators, and drug and medical device regulators. While there is no shortage of books that have sought to expose the misconduct of the pharmaceutical industry (one thinks of the books of Braithwaite, Kassirer, Angell, Moynihan and Goldacre), I finished this book with the feeling that things are getting worse and not better.

The author is a Danish physician with expertise in clinical trials and statistics, and previous experience working in the pharmaceutical industry. He understands the need to substantiate the allegations he makes and provides extensive publicly available documentation covering at least 30 pharmaceutical companies. The book is well written and well planned, with 22 chapters, each addressing discrete issues. This makes it easy to read and his arguments easy to follow.

His criticisms of the industry are wideranging. In the early chapters, the author identifies fraudulent conduct by several big companies, many involving settlements of billions of dollars, and convincingly compares this conduct with the modus operandi of crime syndicates. Subsequent chapters address themes such as the impotence of drug regulators, lack of efficacy of many new drugs, concealment of clinical trial data including serious adverse effects, conflicts of interest at medical journals, alleged corruptive influence…

email